Omentin-1 (Intelectin-1/ITLN1): Omental Adipose-Derived Insulin Sensitizer and Anti-Inflammatory Adipokine in Cardiovascular Research

# Omentin-1 (Intelectin-1/ITLN1): Omental Adipose-Derived Insulin Sensitizer and Anti-Inflammatory Adipokine in Cardiovascular Research

Omentin-1 is a 34-kDa secreted protein produced predominantly in the stromal-vascular fraction (SVF) of omental visceral adipose tissue and circulating in plasma at nanomolar concentrations. Originally identified as intestinal lactoferrin receptor and later re-characterized as a Ca²⁺-dependent carbohydrate-binding lectin (intelectin-1), omentin-1 was established as an adipokine by Yang et al. in 2006 and has since emerged as a compelling "anti-metabolic syndrome" adipokine — one of the few adipokines that is reduced (rather than elevated) in obesity and insulin resistance. Its biology spans insulin signaling enhancement, anti-inflammatory modulation, cardiovascular protection, and innate immune lectin function, making it a multifunctional homeostatic factor whose decline in metabolic disease may represent a clinically significant loss of protective signaling.

Discovery and Nomenclatural History

The omentin story begins with two distinct threads of research that converged on the same protein:

• •It was secreted in significant quantities by omental fat explants and the stromal-vascular fraction (SVF)
• •It was not (or minimally) produced by mature adipocytes themselves, but predominantly by stromal cells (macrophages, endothelial cells, fibroblasts, preadipocytes) within the SVF
• •Recombinant omentin enhanced insulin-stimulated glucose uptake in isolated adipocytes
• •Plasma omentin was reduced in obese compared to lean subjects

The protein is also referred to as intestinal lactoferrin receptor (hILR) in some literature. The preferred current nomenclature is omentin-1 for the ITLN1 product (the predominant circulating form) and omentin-2 for the ITLN2 product (which is detectable but less studied and does not circulate as abundantly).

Gene, Protein Structure, and Lectin Function

ITLN1 Gene and Protein

The human ITLN1 gene is located on chromosome 1q23.3, a region with known associations to metabolic syndrome in GWAS studies. It encodes a 313-amino acid precursor with a signal peptide (residues 1-26) and a 287-amino acid mature protein (molecular weight ~34 kDa per monomer). Omentin-1 circulates as a homotrimer (linked by disulfide bonds), giving a native size of approximately 120 kDa on non-reducing SDS-PAGE.

The protein structure features a fibrinogen-related domain (FReD) at the C-terminus — a domain found in multiple secreted proteins including ficolins, angiopoietins, and tenascins. The FReD domain contains the carbohydrate recognition site and mediates Ca²⁺-dependent binding to the galactose-containing carbohydrate D-galactofuranose, which is found in the cell walls of certain bacteria and parasites but is absent from mammalian cells. This carbohydrate specificity makes omentin-1 a pattern recognition molecule in the innate immune lectin pathway, similar to ficolins and mannose-binding lectin (MBL).

The N-terminal region contains a coiled-coil domain that contributes to trimerization. Glycosylation (N-linked) at multiple sites stabilizes the protein and may influence receptor binding.

ITLN2: The paralog ITLN2 (chromosome 1q23.3, adjacent to ITLN1) encodes intelectin-2, which shares ~93% amino acid identity with omentin-1 but shows somewhat different tissue expression (more restricted to intestinal epithelium and Paneth cells). Intelectin-2 also has carbohydrate binding activity but is not well-characterized as an adipokine.

Lectin and Bacterial Binding Properties

The Ca²⁺-dependent carbohydrate binding specificity of omentin-1 for D-galactofuranose is noteworthy because this unusual sugar is present in mycobacterial arabinogalactan (component of the cell wall of Mycobacterium tuberculosis and related mycobacteria), in the cell walls of E. coli lipopolysaccharide variants, and in parasites like Trypanosoma species. Importantly, D-galactofuranose is absent from mammalian glycoproteins, making it an ideal innate immune recognition target.

Omentin-1 binds M. tuberculosis bacilli through galactofuranose recognition and promotes their phagocytosis by macrophages, functioning as an opsonin in the lectin complement pathway. The intestinal expression of ITLN1 in enterocytes and Paneth cells (especially in response to parasitic infections) suggests omentin-1 participates in intestinal innate defense against parasites and bacteria.

This lectin function in immunity is conceptually distinct from its adipokine functions in metabolism, illustrating the multifunctional nature of secreted proteins that have been repurposed for multiple biological roles during evolution.

Regulation of Omentin-1 Expression and Secretion

The regulation of omentin-1 is important because its reduced levels in metabolic disease represent either a primary driver of pathology or a downstream consequence:

Reduced by: Obesity (BMI correlation, negative), insulin resistance (HOMA-IR correlation, negative), inflammation (TNF-α, IL-6 suppress ITLN1 in adipose SVF), hyperglycemia (in vitro), visceral fat expansion, and polycystic ovary syndrome (PCOS).

Increased by: Weight loss (caloric restriction, exercise, bariatric surgery consistently raise plasma omentin-1), insulin sensitizers (pioglitazone, a PPARγ agonist, increases omentin-1 expression), metformin (modest increase in some studies), and anti-inflammatory interventions.

Transcriptional regulation: ITLN1 promoter analysis reveals binding sites for PPARγ response elements (consistent with insulin sensitizer regulation), NF-κB (inflammation-responsive negative regulation), and STAT3 (leptin signaling → STAT3 may suppress omentin).

Tissue-specific expression: The preferential expression in omental SVF over subcutaneous SVF means that the ratio of visceral to subcutaneous adipose tissue determines how much omentin-1 is available per unit adipose mass. As obesity shifts fat distribution toward visceral (omental) fat, the expected elevation in omentin output per unit tissue is overridden by the strong negative regulatory effects of inflammation and insulin resistance on ITLN1 expression.

Metabolic Functions

Insulin Sensitization

Omentin-1's most established metabolic function is enhancement of insulin-stimulated glucose uptake in adipocytes. Yang et al. (2006) demonstrated that recombinant omentin-1 at 100-500 ng/mL significantly potentiated insulin-stimulated GLUT4 translocation and glucose uptake in isolated human adipocytes without activating GLUT4 translocation on its own (i.e., it sensitizes rather than mimics insulin).

The molecular mechanism of insulin sensitization involves:

1. Omentin-1 activates Akt (protein kinase B) at Ser473 via PI3K-dependent mechanisms in adipocytes

2. Activated Akt phosphorylates AS160 (TBC1D4), promoting GLUT4 vesicle translocation

3. Omentin-1 also activates AMPK (AMP-activated protein kinase) in some cell types, potentially contributing to insulin-independent glucose uptake

Pharmacological PI3K inhibition (wortmannin) blocks omentin-1's insulin-sensitizing effect, confirming PI3K pathway dependence. The receptor that mediates omentin-1's cellular effects has not been definitively identified, which is a significant gap — the molecular entry point for omentin signaling remains unknown.

Anti-Inflammatory Effects in Adipose Tissue

In macrophages and adipocytes, omentin-1 suppresses pro-inflammatory signaling:

• •Omentin-1 at physiological concentrations (100-400 ng/mL) suppresses LPS-induced TNF-α and IL-6 production from macrophages
• •Suppression of NF-κB nuclear translocation is the primary mechanism, with omentin-1 reducing IKKβ phosphorylation and IκBα degradation
• •Omentin-1 also activates Nrf2 (NF-E2-related factor 2), promoting antioxidant gene expression (HO-1, NQO1)
• •In TNF-α-treated adipocytes, omentin-1 reduces NF-κB activation and the downstream upregulation of IL-6 and MCP-1

Given that adipose tissue inflammation is a central driver of insulin resistance in obesity, the reduction of omentin-1 in obese adipose tissue creates a feedforward loop: less omentin-1 → more adipose inflammation → more insulin resistance → further ITLN1 suppression.

Cardiovascular Biology

Omentin-1 has attracted significant attention in cardiovascular research due to its protective effects in multiple cardiac and vascular pathologies.

Anti-Atherogenic Properties

Pan et al. demonstrated that omentin-1 inhibits TNF-α-induced VCAM-1 and ICAM-1 expression in endothelial cells, key adhesion molecules for monocyte recruitment in early atherogenesis. This effect is mediated by PI3K/Akt activation and NF-κB suppression. Omentin-1 also reduces endothelin-1 production from endothelial cells, contributing to vasodilation.

In clinical studies, plasma omentin-1 is inversely associated with coronary artery disease (CAD) severity as assessed by coronary angiography, independently of BMI. Patients with acute myocardial infarction (AMI) have significantly lower admission omentin-1 compared to stable angina patients and controls, and lower omentin-1 at admission predicts worse outcomes in some cohorts.

Cardioprotection Against Ischemia-Reperfusion

In isolated heart models and in vivo ischemia-reperfusion experiments, omentin-1 pretreatment:

• •Reduces infarct size by 20-35%
• •Reduces cardiomyocyte apoptosis (via Akt/ERK survival signaling)
• •Reduces reactive oxygen species production during reperfusion
• •Suppresses inflammatory cytokine production in reperfused myocardium

The molecular mechanism involves AMPK and Akt activation in cardiomyocytes, converging on inhibition of mitochondrial permeability transition pore (mPTP) opening.

Heart Failure

An interesting paradox emerges in heart failure: while plasma omentin-1 is generally reduced in metabolic disease, it is elevated in some heart failure cohorts, particularly in advanced disease. This counterintuitive finding may reflect either compensatory upregulation or, alternatively, that elevated omentin in heart failure reflects the underlying cardiomyocyte stress response rather than adipose-derived secretion. Differentiating the source and functional significance of elevated omentin-1 in heart failure is an unresolved research question.

Hypertension and Vascular Function

Plasma omentin-1 is inversely associated with blood pressure in multiple cross-sectional studies. Mechanistically, omentin-1 promotes endothelium-dependent vasodilation by:

1. Increasing eNOS phosphorylation (Ser1177) and NO production in endothelial cells via PI3K/Akt

2. Reducing endothelin-1 (ET-1) production

3. Suppressing NADPH oxidase activity, reducing superoxide and preserving NO bioavailability

Clinical Associations and Biomarker Potential

The inverse correlation between plasma omentin-1 and cardiometabolic disease severity has been documented across multiple populations:

• •Type 2 diabetes: Omentin-1 is significantly lower in T2DM vs. normoglycemic controls, inversely correlates with HbA1c and fasting glucose
• •Metabolic syndrome: Lower in subjects meeting MetS criteria; each additional MetS criterion associates with progressively lower omentin-1
• •PCOS: Dramatically reduced in PCOS compared to healthy controls; inversely correlates with testosterone and LH levels
• •Non-alcoholic fatty liver disease (NAFLD): Lower in NAFLD subjects; inversely correlates with liver steatosis grade
• •Psoriasis and rheumatoid arthritis: Reduced in active inflammatory disease; increases with anti-inflammatory treatment
• •Thyroid disease: Elevated in hypothyroidism (possibly due to reduced metabolic clearance), reduced in hyperthyroidism
• •Pregnancy: Plasma omentin-1 is lower in gestational diabetes compared to normal pregnancy; reduced in preeclampsia

The reference range for plasma omentin-1 in healthy adults is approximately 300-800 ng/mL, with significant variability. Commercial ELISA kits are available for research use. No standardized clinical assay exists yet.

Research Tools and Experimental Systems

Current Research Frontiers

Receptor identification: The omentin-1 receptor remains unidentified — a significant gap that limits mechanistic understanding and drug development. High-throughput receptor deorphanization approaches (AlphaFold-assisted structural docking, proximity labeling mass spectrometry) are being applied to this problem.

Therapeutic potential: Given its insulin-sensitizing and anti-inflammatory profile, recombinant omentin-1 administration has been explored in animal models of metabolic syndrome and cardiac injury. A long-acting omentin-1 analog or Fc fusion protein would be required for clinical development. PPARγ agonists (pioglitazone) and other interventions that raise omentin-1 as part of a broader beneficial profile may explain some of their metabolic benefits through this mechanism.

Gut immunity and microbiome: ITLN1 expression in intestinal Paneth cells and its galactofuranose-binding specificity position omentin-1 in the emerging field of intestinal lectin biology and its relationship to the gut microbiome. D-galactofuranose is present on some gut commensal bacteria, raising the possibility that intestinal omentin-1 shapes microbiota composition through selective binding and phagocytosis promotion.

Omentin in respiratory disease: ITLN1 is expressed in lung airway epithelium, and omentin-1 has been found in airway secretions. A genetic association between ITLN1 variants and susceptibility to asthma and inflammatory bowel disease has been reported, suggesting roles in mucosal immunity beyond its adipokine functions.

ITLN1 genetics and metabolic syndrome GWAS: The chromosome 1q23.3 region containing ITLN1 has shown suggestive associations with type 2 diabetes and obesity in some genome-wide association studies, motivating finer mapping of ITLN1 variants for their functional effects on omentin-1 expression and metabolic risk.

Conclusion

Omentin-1 stands as a member of an elite group of anti-inflammatory, insulin-sensitizing adipokines — together with adiponectin, it represents the "protective" adipokine axis that declines in metabolic disease, contrasting with the "harmful" adipokines (leptin, resistin, chemerin, visfatin) that increase with adiposity. Its preferential production in omental fat SVF, reduction in obesity and insulin resistance, and proven beneficial effects on insulin signaling, endothelial function, cardiomyocyte survival, and inflammatory suppression position it as both a biomarker of cardiometabolic health and a potential therapeutic agent. The major research gap — absence of a known receptor — prevents full mechanistic characterization and limits drug development efforts. Recombinant human omentin-1 protein and validated ELISA kits for plasma measurement are the primary research tools; transgenic mouse models overexpressing omentin-1 in adipose tissue have provided in vivo cardiovascular and metabolic phenotyping data. As with adiponectin, interventions that preserve or restore omentin-1 levels (weight loss, PPARγ agonism, anti-inflammatory therapies) may partly explain their cardiometabolic benefits through this lectin adipokine axis.

Key References

2. Tan BK, Adya R, Farhatullah S, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome. Diabetes. 2008;57(3):801-808. PMID: 18184927

4. Kazama K, Usui T, Okada M, et al. Omentin plays an anti-inflammatory role through inhibition of TNF-α-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol. 2012;686(1-3):116-123. PMID: 22503987

5. Saito S, Hirose N, Iwata A, et al. Omentin-1 attenuates cardiac ischemia/reperfusion injury via PI3K/Akt signaling pathway. Front Pharmacol. 2020;11:328. PMID: 32265698

8. Shibata R, Takahashi R, Ito M, et al. Association of a fat-derived plasma protein omentin with carotid artery IMT. J Clin Endocrinol Metab. 2012;97(2):E339-43. PMID: 22090093

9. Auguet T, Quintero Y, Riesco D, et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet. 2011;12:60. PMID: 21507261

10. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006;116(6):1494-1505. PMID: 16691291

---

This article is intended for Research Use Only (RUO). The information provided describes laboratory research findings and does not constitute medical advice. Omentin-1 and related intelectin proteins are research tools and investigational agents. All research applications must comply with applicable institutional, local, and national regulations.